MBX Biosciences, Inc. Common Stock
NASDAQ Global SelectTotal Valuation
MBX Biosciences, Inc. Common Stock carries a market capitalization of 2.94B, placing it among publicly traded companies globally. Its enterprise value stands at 2.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.94B |
| Enterprise Value | 2.23B |
Share Statistics
MBX Biosciences, Inc. Common Stock currently has 47.95M shares outstanding.
| Shares Outstanding | 47.95M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 6.46 |
| P/TBV Ratio | 6.46 |
| P/FCF Ratio | -29.85 |
| P/OCF Ratio | -28.94 |
Financial Position
MBX Biosciences, Inc. Common Stock maintains a current ratio of 18.08, meaning it holds 18.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 18.08 |
| Quick Ratio | 17.82 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -33.17 |
| Return on Assets (ROA) | -31.25 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
MBX Biosciences, Inc. Common Stock's stock has gained approximately 377.70898% over the past 52 weeks. The 50-day moving average sits at 62.77, while the 200-day moving average is 40.54.
| Beta (5Y) | N/A |
| 52-Week Price Change | 377.70898% |
| 50-Day Moving Average | 62.77 |
| 200-Day Moving Average | 40.54 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -117.66M, while operating income came in at -117.92M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -117.92M |
| Pretax Income | -104.29M |
| Net Income | -104.29M |
| EBITDA | -117.66M |
| EBIT | -117.92M |
| Earnings Per Share (EPS) | -2.41 |
Balance Sheet
MBX Biosciences, Inc. Common Stock holds 418.58M in cash and equivalents against 3.34M in total debt, resulting in a net debt position of -54.12M. Total book value stands at 409.54M, with working capital of 404.20M providing operational flexibility.
| Cash & Cash Equivalents | 418.58M |
| Total Debt | 3.34M |
| Net Debt | -54.12M |
| Equity (Book Value) | 409.54M |
| Book Value Per Share | 8.54 |
| Working Capital | 404.20M |
Cash Flow
MBX Biosciences, Inc. Common Stock produced -82.67M in operating cash flow over the past twelve months. After subtracting -2.53M in capital expenditures, free cash flow totaled -85.20M - equivalent to -1.97 per share.
| Operating Cash Flow | -82.67M |
| Capital Expenditures | -2.53M |
| Free Cash Flow | -85.20M |
| FCF Per Share | -1.97 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.50 |
| FCF Yield | -3.35 |
Scores
MBX Biosciences, Inc. Common Stock posts an Altman Z-Score of 59.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 59.53 |